All In Biotech

Drug Trial Radar · NCT05302947

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Tocilizumab, Netakimab, and Baricitinib Versus Standard of Care Therapy in Patients With Mild to Moderate COVID-19 - a Retrospective Observational Study

Last checked: Nov 19, 2026Latest source record: Apr 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

154

Actual

Start

Feb 1, 2020

Primary completion

Aug 31, 2020

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Pirogov Russian National Research Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
City Clinical Hospital No.52 of Moscow Healthcare Department
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a retrospective observational cohort study. About 1000 hospital charts of adult patients admitted to the hospital with mild-to-moderate COVID-19 from February to August 2020 were analyzed to evaluate the inflammatory markers and clinical outcomes. The aim of this study was to compare the observed results of targeted immunosuppressive therapy, anti-IL-6R (Tocilizumab), anti-IL-17A (Netakimab), and JAK1/JAK2 inhibitor (Baricitinib), with standard-of-care (SOC) therapy. The investigators hypothesize that, as compared to SOC therapy, all target drugs will demonstrate at least similar beneficial effects. This observation may additionally support a rational choice for mild-to-moderate COVID-19 treatment strategy, considering the general safety profile and patient-specific limitations.

Conditions

  • COVID-19
  • Mild to Moderate

Interventions

  • Baricitinib Oral TabletDrug

    Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition

  • Tocilizumab InjectionDrug

    Tocilizumab was administered by a single intravenous dose of 400 mg

  • NetakimabDrug

    Netakimab was administered by a single subcutaneous injection of 120 mg

  • Standard of care therapyOther

    SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changing in the level of C-reactive proteinTime frame: 5 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • City Clinical Hospital No. 52 of the Department of Health of the City of Moscow

    Moscow, Russia

  • Pirogov Russian National Research Medical University

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.